<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03502031</url>
  </required_header>
  <id_info>
    <org_study_id>NN-01</org_study_id>
    <nct_id>NCT03502031</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Two Year Spnol and Maximal R Blockad Therapy</brief_title>
  <acronym>MRA-ACE</acronym>
  <official_title>Examining the Safety andType II Diabetic ne in AAmericans and Other Patient Cohorts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>James A. Tumlin, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NephroNet, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      NephroNet proposes to examine whether combining Spironolactone with maximal RAAblockade will&#xD;
      further reduce urinary protein at one year and whether prolonged therapy 24 months) is able&#xD;
      to slow the decline in GFR. Because of combination MRand RAAS therapsignificantly increases&#xD;
      the risk for clinically significantcccc, the investigators also whether the addition of&#xD;
      Patironts facilitates the use of combination therapy and allows a larger proportion of&#xD;
      diabetic patients the potential benefit of combination therapy on renal function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, open-labeled study of 7patients with overt Type II diabetic nephropathy and &gt;500&#xD;
      mg/gm UP/Cr ratio that will mnmnmnn be randomized to maximal RAAS blockade alone or in&#xD;
      combinatio (25 mg) for 2months. An analysis of the change in 1months and change in eGFR&#xD;
      a2months will be performed&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Bb&#xD;
  </why_stopped>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Safety anxxxxxxof maximally tolerated RAAS blockade and Spironolactone therapy on urinary proteinuria andogression of nephropathy in African Americans and other patient cohorts</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combination Therapy - RAAS inhibition and Spironolactone</measure>
    <time_frame>12 months</time_frame>
    <description>To determine whether combination therapy with maximally tolerated RAAS inhibition and Spironolactone is superior to RAAS inhibition alone in lowering the UP/Cr ratio at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combination Therapy - RAAS inhibition and Spironolactone</measure>
    <time_frame>24 months</time_frame>
    <description>To determine whether combination therapy with maximally tolerated RAAS inhibition and Spironolactone is superior to RAAS inhibition alone in slowing the progression of renal disease as evidenced by changes in GFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination Therapy - RAAS inhibition and Spironolactone</measure>
    <time_frame>12 and 24 months</time_frame>
    <description>To determine the percentage of patients in the maximal RAAS blockade group and those receiving combination RAAS + Spironolactone therapy developing clinically significant hyperkalemia as defined as a serum K+ level greater than 5.5 meq/L. We will determine the percentage of patients that require &quot;Patiromer-Rescue&quot; for K+ &gt; 5.5 meq/L and the percentage of patients maintained with serum K+ less than 5.5 meq/L</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Renal Insufficiency, Chronic</condition>
  <condition>Diabetic Nephropathy Type 2</condition>
  <arm_group>
    <arm_group_label>Renin-Angioten (RAAombination with Spironolactone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with overt Type II diabetic nephropathy and &gt;5 mg/gm UP/Cr ratio that wi to maximal RAAS blockade (ACE/ARB-such as Lisinopril 2000mg, Losartan in combination with Spironolactone (25 m Qday) for 24 months. The determination of maximum tolerwill be left to the discretion anyone at the site</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Renin-Angiotensin (RAAS) bers (ACE/ARB) alone</intervention_name>
    <description>maximal RAAS blockade alone for 2months.</description>
    <arm_group_label>Renin-Angioten (RAAombination with Spironolactone</arm_group_label>
    <other_name>Lispril, Enalapril, Perindopril etc., Losarta, Valsar etc.,</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Renin-Angiotensin (RAAS) blockers in combination with Spironolactone</intervention_name>
    <description>maximal RAAS blockade alone or in combination with Spironolactone (25 mg) for 1024 months.</description>
    <arm_group_label>Renin-Angioten (RAAombination with Spironolactone</arm_group_label>
    <other_name>Lisinopril, Enalapril, Perindopril etc, Losartan, Valsartan etc,</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age above 18&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  Patients with Type II diabetes mellitus must be receiving oral agents or insulin&#xD;
             injections at the time of randomization&#xD;
&#xD;
          -  All eligible patients will be on a stable, maximum tolerated dose of an ACE or ARB for&#xD;
             2 weeks prior to randomization.&#xD;
&#xD;
          -  Note: The determination of m tolerated ACE-ARB therapy will be left to the discretion&#xD;
             of the site principal investigator&#xD;
&#xD;
          -  All eligible patients will have hypertension targetblood pressure of &lt; 140/90mm Hg.&#xD;
&#xD;
          -  Antihypertensive therapy may be adjusted to achieve the target blood pressure prior to&#xD;
             the time of randomization.&#xD;
&#xD;
          -  ACE or ARB therapy will be the primary antihypertensive therapy used for blood&#xD;
             pressure control and will be titrated to the highest tolerated dose to achieve a&#xD;
             target blood pressure of &lt;Patients requiring additional medications to achieve the&#xD;
             target blood pressure will use antihypertensive agents that have neutral effects on&#xD;
             urinary proteinuria (e.g. Hydralazine or long acting Dihydropyridine calcium channel&#xD;
             blockers etc.). The final choice of additional medications will be left to the&#xD;
             discretion of the site principal investigator (PI)&#xD;
&#xD;
          -  Patients with an average urine protein to creatinine (UP/Cr) ratio that is &gt; 500 mg/gm&#xD;
             from the average of two historical value within one year prior to randomization will&#xD;
             be considered eligible for study entry.&#xD;
&#xD;
          -  Patients with a baseline K+ of &gt;5.5 meq/l on maximum tolerated ACE-ARB therapy during&#xD;
             the screening period can be treated with 8.4 grams of Patiromer for 7 days. If at the&#xD;
             end of 7days the serum K+ is &lt; 5.0 meq/liter the patient will be considered eligible&#xD;
             to participate in the study. If at the end of 7 days the serum K+ &gt;5.0 meq/l the dose&#xD;
             of Patiromer can be increased to 16.8 grams. If at the end of 7 days the serum K+ is &lt;&#xD;
             5.0 meq/L, the patient will be considered eligible for study entry. If after 7 days at&#xD;
             the higher dose of Patiromer the serum K+ &gt;5.0, the patient will be ineligible for&#xD;
             study participation.&#xD;
&#xD;
          -  Patients with an estimated GFR by CKD-Epi equation1.73 m2&#xD;
&#xD;
          -  Female patients will be required to undergo routine birth control measures&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Estimated GFR by MDRD &lt;20 mls/min/1.73 M2 using the CKD-Epi equation&#xD;
&#xD;
          -  Patients with serum K+ &gt; 5.0 meq/l while taking 16.8 gms/day of Patiromer&#xD;
&#xD;
          -  Patients with history of Type mellitus&#xD;
&#xD;
          -  Patients with HgbA1c &gt; 11%&#xD;
&#xD;
          -  Pregnant or breast-feeding female patients&#xD;
&#xD;
          -  Female patients unwilling to receive estrogen or progesterone based birth control or&#xD;
             are unwilling or unable to use conventional barrier birth control methods.&#xD;
&#xD;
          -  Patients with known allergy or intolerance tor Spironolactone therapy&#xD;
&#xD;
          -  Patients taking oral or IV digoxin&#xD;
&#xD;
          -  Patients receiving chronic steroids &gt; 10 mg/day oral Prednisone&#xD;
&#xD;
          -  Patient that do not have minimum of 3 recorded eGFR determinations within 2 years&#xD;
             prior to study randomization&#xD;
&#xD;
          -  Concurrent use of Amiloride, Triamteren, Aliskerin, or other Aldosterone antagonists&#xD;
             Patients receiving any of the above medications will be considered eligible for study&#xD;
             participation after a 120week wash-out&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Georgia Nephrology Research Institute</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 13, 2017</study_first_submitted>
  <study_first_submitted_qc>April 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>NephroNet, Inc.</investigator_affiliation>
    <investigator_full_name>James A. Tumlin, MD</investigator_full_name>
    <investigator_title>Sponsonvestigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Perindopril</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

